Summary & Overview
CPT 0236U: Genomic Unity® SMN1/SMN2 Analysis
CPT code 0236U denotes a proprietary genomic laboratory test — the Genomic Unity® SMN1/2 Analysis from Variantyx Inc. — that uses PCR-free whole genome sequencing and algorithmic analysis of blood or saliva specimens to assess variants in the SMN1 and SMN2 genes related to spinal muscular atrophy and related conditions. This PLA code identifies a single, manufacturer-specific test and is important nationally as genomic diagnostics expand into clinical care, prenatal and neuromuscular evaluation pathways, and payer coverage decisions for high-cost molecular tests.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical purpose, typical service setting, and what coverage conversations center on for proprietary genomic assays. The publication summarizes benchmarking concepts relevant to PLA codes, highlights policy and coding considerations that affect national utilization and reimbursement, and provides clinical context about when SMN1/SMN2 analysis is relevant. Data not available in the input for detailed payer policies, associated taxonomies, and ICD-10 diagnosis mapping is noted where applicable.
Billing Code Overview
CPT code 0236U is a Proprietary Laboratory Analyses (PLA) code for the Genomic Unity® SMN1/2 Analysis from Variantyx Inc. The test evaluates the survival of motor neuron 1, telomeric (SMN1) and survival of motor neuron 2, centromeric (SMN2) genes using a PCR-free whole genome sequencing (WGS) platform with algorithmic data analysis to detect variants relevant to conditions such as spinal muscular atrophy.
Service type: Genomic sequencing and targeted gene analysis using PCR-free whole genome sequencing with algorithmic interpretation
Typical site of service: Clinical laboratory (blood or saliva specimen collection with testing performed in a specialized molecular/genomics laboratory)
Clinical & Coding Specifications
Clinical Context
A pediatric or adult patient with a personal or family history suggestive of spinal muscular atrophy (SMA) presents for genetic testing to confirm carrier status, diagnostic evaluation of neuromuscular weakness, or to inform reproductive planning. Typical indications include: progressive proximal muscle weakness, hypotonia in infants, delayed motor milestones, or a known family history of SMN1 pathogenic variants. The clinician (pediatric neurologist, medical geneticist, or genetic counselor) orders the Genomic Unity® SMN1/2 Analysis (0236U) using a blood or saliva specimen. The specimen is collected at an outpatient clinic, hospital ambulatory lab, or at-home collection kit per laboratory instructions and shipped to Variantyx Inc. for processing.
Laboratory workflow: the lab performs PCR-free whole genome sequencing (WGS) with algorithmic analysis focused on copy number and sequence variants in SMN1 and SMN2. Results include SMN1 copy number, SMN2 copy number, and detection of pathogenic or likely pathogenic sequence variants relevant to SMA. The laboratory report is returned to the ordering provider with interpretation to support diagnostic confirmation, carrier screening, prognostic counseling, or therapeutic decision-making such as eligibility for SMA-targeted therapies or inclusion in clinical trials.
Typical site of service: outpatient clinic, hospital outpatient laboratory, or reference laboratory with remote specimen collection.
Coding Specifications
| Modifier | Description | When to Use |
|---|